Table 4

Comparison of SCT and no-SCT patient outcomes according to oncogenetic markers and early MRD response (time-dependent analysis)

PatientsSCT patientsCIR HR*95% CIP*PinteractionRFS HR*95% CIP*PinteractionOS HR†95% CIP†Pinteraction
Focal IKZF1 deletion (BCP-ALL)               
 Yes 58 29 0.43 0.18-1.07 .07 .72 0.42 0.19-0.89 .025 .078 0.35 0.16-0.75 .007 .071 
 No 148 80 0.44 0.22-0.90 .025  0.83 0.48-1.44 .51  0.87 0.49-1.55 .64  
NOTCH1/FBXW7 mutation (T-ALL)               
 Yes 86 53 0.36 0.13-1.01 .053 .46 0.68 0.28-1.65 .39 .61 0.67 0.26-1.73 .41 .68 
 No 53 28 0.60 0.26-1.41 .25  1.03 0.45-2.19 .93  1.01 0.44-2.30 .98  
4-gene classifier (T-ALL)               
 High-risk 69 35 0.58 0.28-1.23 .15 .41 1.01 0.53-1.95 .97 .98 0.96 0.46-1.98 .91 .93 
 Low-risk 59 37 0.27 0.05-1.45 .13  0.82 0.23-2.91 .76  0.75 0.20-2.79 .66  
MRD1 level ≥10−3 or late CR (all)               
 Yes 105 59 0.39 0.21-0.71 .002 .24 0.40 0.23-0.69 .001 .001 0.41 0.23-0.74 .003 .002 
 No 173 94 0.63 0.33-1.20 .16  1.37 0.81-2.32 .24  1.47 0.85-2.54 .16  
MRD1 level ≥10−3 or late CR (BCP-ALL)               
 Yes 66 37 0.50 0.24-1.06 .069 .99 0.36 0.18-0.73 .004 .007 0.43 .21-.90 .025 .050 
 No 115 64 0.55 0.24-1.29 .17  1.34 0.70-2.54 .38  1.13 .61-2.11 .70  
MRD1 level ≥10−3 or late CR (T-ALL)               
 Yes 39 22 0.25 0.08-0.75 .014 .053 0.48 0.19-1.19 .11 .038 0.40 .15-1.06 .066 .010 
 No 58 30 0.83 0.30-2.30 .72  1.42 0.57-3.53 .46  2.67 .83-8.55 .10  
PatientsSCT patientsCIR HR*95% CIP*PinteractionRFS HR*95% CIP*PinteractionOS HR†95% CIP†Pinteraction
Focal IKZF1 deletion (BCP-ALL)               
 Yes 58 29 0.43 0.18-1.07 .07 .72 0.42 0.19-0.89 .025 .078 0.35 0.16-0.75 .007 .071 
 No 148 80 0.44 0.22-0.90 .025  0.83 0.48-1.44 .51  0.87 0.49-1.55 .64  
NOTCH1/FBXW7 mutation (T-ALL)               
 Yes 86 53 0.36 0.13-1.01 .053 .46 0.68 0.28-1.65 .39 .61 0.67 0.26-1.73 .41 .68 
 No 53 28 0.60 0.26-1.41 .25  1.03 0.45-2.19 .93  1.01 0.44-2.30 .98  
4-gene classifier (T-ALL)               
 High-risk 69 35 0.58 0.28-1.23 .15 .41 1.01 0.53-1.95 .97 .98 0.96 0.46-1.98 .91 .93 
 Low-risk 59 37 0.27 0.05-1.45 .13  0.82 0.23-2.91 .76  0.75 0.20-2.79 .66  
MRD1 level ≥10−3 or late CR (all)               
 Yes 105 59 0.39 0.21-0.71 .002 .24 0.40 0.23-0.69 .001 .001 0.41 0.23-0.74 .003 .002 
 No 173 94 0.63 0.33-1.20 .16  1.37 0.81-2.32 .24  1.47 0.85-2.54 .16  
MRD1 level ≥10−3 or late CR (BCP-ALL)               
 Yes 66 37 0.50 0.24-1.06 .069 .99 0.36 0.18-0.73 .004 .007 0.43 .21-.90 .025 .050 
 No 115 64 0.55 0.24-1.29 .17  1.34 0.70-2.54 .38  1.13 .61-2.11 .70  
MRD1 level ≥10−3 or late CR (T-ALL)               
 Yes 39 22 0.25 0.08-0.75 .014 .053 0.48 0.19-1.19 .11 .038 0.40 .15-1.06 .066 .010 
 No 58 30 0.83 0.30-2.30 .72  1.42 0.57-3.53 .46  2.67 .83-8.55 .10  
*

HR in SCT vs no-SCT cohort by the Andersen-Gill model.

†

OS comparisons were performed by using a 45-day landmark period, excluding patients who died or relapsed during the first 45 days following CR achievement from comparisons (see “Statistical methods” section).

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal